Skip to content
Cycle Pharmaceuticals Logo Cycle Pharmaceuticals Logo Cycle Pharmaceuticals Logo
  • About us
    • EXECUTIVE TEAM
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • CORPORATE SOCIAL RESPONSIBILITY
    • COMPLIANCE & ETHICS
    • CONTACT US
  • SUPPORT FOR LIFE & PRODUCTS
    • PRODUCTS
    • REPORTING AN ADVERSE EVENT
  • PIPELINE
    • TECHNOLOGY PARTNERSHIPS
    • COMMERCIAL PARTNERSHIPS
  • PATIENTS & ADVOCACY
    • PATIENT ADVOCACY
    • PATIENT STORIES
    • COMPASSIONATE USE
    • NAMED PATIENT PROGRAM
  • NEWS
  • CAREERS
Home/Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)/covid-icon-large-wide
Previous

covid-icon-large-wide

By Kierah Bircham|2020-07-30T15:22:03+01:00July 30th, 2020|

SHARE THIS ARTICLE :

FacebookTwitterLinkedIn

About the Author: Kierah Bircham

logo_footer

  • Legal Policies
  • REPORTING AN ADVERSE EVENT
  • Contact

CYCLE Pharmaceuticals Limited is registered in England and Wales. Registration number 07933058.

GL-0043 (Date of Preparation: September 2020)

UK: +44 1223 354118
US: +1 800 903 1793
info@cyclepharma.com

Go to Top